1. Home
  2. DLNG vs MDWD Comparison

DLNG vs MDWD Comparison

Compare DLNG & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dynagas LNG Partners LP

DLNG

Dynagas LNG Partners LP

N/A

Current Price

$3.18

Market Cap

140.8M

ML Signal

N/A

Logo MediWound Ltd.

MDWD

MediWound Ltd.

N/A

Current Price

$13.54

Market Cap

162.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DLNG
MDWD
Founded
2013
2000
Country
Greece
Israel
Employees
N/A
N/A
Industry
Marine Transportation
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
140.8M
162.2M
IPO Year
2013
2013

Fundamental Metrics

Financial Performance
Metric
DLNG
MDWD
Price
$3.18
$13.54
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
★ $30.67
AVG Volume (30 Days)
61.2K
★ 95.0K
Earning Date
11-19-2026
11-12-2026
Dividend Yield
★ 6.13%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$39.60
Revenue Next Year
$1.10
$34.34
P/E Ratio
$3.04
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.25
$11.80
52 Week High
$4.45
$19.70

Technical Indicators

Market Signals
Indicator
DLNG
MDWD
Relative Strength Index (RSI) 27.02 55.55
Support Level N/A $12.76
Resistance Level $3.96 $14.06
Average True Range (ATR) 0.09 0.56
MACD -0.01 0.18
Stochastic Oscillator 11.96 70.32

Price Performance

Historical Comparison
DLNG
MDWD

About DLNG Dynagas LNG Partners LP

Dynagas LNG Partners LP is a limited partnership company focused on owning and operating high specification and versatile LNG carriers that are employed on multi-year contracts with international energy companies, providing the benefits of stable cash flows and high utilization rates. The company defines charters of two years or more as multi-year charters. Its current LNG Carrier fleet is optimized for trading flexibility. In addition to conventional trade, part of LNG Carrier fleet is assigned with Ice Class 1A FS notation and is winterized, which enables trade in subzero and ice bound conditions.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: